482-25-7

Basic information

• Product Name: BYAKANGELICIN
• Synonyms: Biacangelicin;Bjacangelicin;Bjakangelicin;Byankagelicine;9-[(2R)-2,3-dihydroxy-3-methyl-butoxy]-4-methoxy-furo[3,2-g]chromen-7-one;9-[(2R)-2,3-dihydroxy-3-methylbutoxy]-4-methoxyfuro[3,2-g]chromen-7-one;BYAKANGELICIN (P);5-Methoxy-8-(2,3-dihydroxy-3-methylbutoxy)psoralene
• CAS NO: 482-25-7
• Molecular Formula: C₁₇H₁₈O₇
• Molecular Weight: 334.32062
• Mol File: 482-25-7.mol

Chemical Properties

• Melting Point: 123-124℃
• Boiling Point: 571.5°Cat760mmHg
• Flash Point: 299.4°C
• Appearance: /
• Density: 1.373
• Vapor Pressure: 6.69E-14mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: ?20°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 13.67±0.20(Predicted)
• CAS DataBase Reference: BYAKANGELICIN(CAS DataBase Reference)
• NIST Chemistry Reference: BYAKANGELICIN(482-25-7)
• EPA Substance Registry System: BYAKANGELICIN(482-25-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 482-25-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
BYAKANGELICIN is used as an inhibitor of sex hormones, affecting the catabolism of endogenous hormones. This property makes it a potential candidate for the development of drugs targeting hormone-related conditions.
Used in Hepatocyte Applications:
BYAKANGELICIN directly affects the cytochrome P450 isoform (CY) P3A4 in human hepatocytes, which is an essential enzyme involved in the metabolism of various drugs and substances in the liver. This interaction with CYP3A4 can be utilized in the development of drugs that modulate the activity of this enzyme, potentially improving the efficacy and safety of certain medications.
Used in Diabetic Complications Treatment:
BYAKANGELICIN is used as an inhibitor of aldose reductase, an enzyme involved in the development of diabetic cataract. By inhibiting this enzyme, BYAKANGELICIN can help in the treatment and prevention of diabetic cataract, a common complication in patients with diabetes.

InChI:InChI=1/C17H18O7/c1-17(2,20)11(18)8-23-16-14-10(6-7-22-14)13(21-3)9-4-5-12(19)24-15(9)16/h4-7,11,18,20H,8H2,1-3H3

Downstream Products

• 61046-59-1 (+/-)-byakangelicol 
• 35214-81-4 4-methoxy-9-(3-methyl-2-oxo-butoxy)-furo[3,2-g]chromen-7-one 

Relevant articles and documents

Benzofuran and coumarin derivatives from the root of Angelica dahurica and their PPAR-γ ligand-binding activity

A phytochemical investigation of the root of Angelica dahurica led to the isolation of benzofuran and coumarin derivatives. This is the first report of the isolation and identification of three furanocoumarin sulfates from A. dahurica root. The structures of a total of twelve undescribed compounds were determined by extensive spectroscopic analysis, including 2D NMR data, hydrolysis, and solvolysis, followed by either physicochemical and spectroscopic data or X-ray crystallographic analysis. The isolated compounds were evaluated for their PPAR-γ ligand-binding activity, and six compounds showed significant PPAR-γ ligand-binding activity. In particular, the undescribed benzofuran derivative, 3-[6,7-furano-9-hydroxy-4-(2″,3″-dihydroxy-3″-methylbutyloxy)]-phenyl propionic acid, exhibited the most potent PPAR-γ ligand-binding activity and accumulated intracellular lipid in 3T3-L1 cells.

Angelicosides I-IV, four undescribed furanocoumarin glycosides from Angelica dahurica roots and their tyrosinase inhibitory activities

Angelica dahurica is an important medicinal plant, which has been widely used in medicines and skin-whitening products. In the investigation of phytochemicals present in A. dahurica roots, three unusual furanocoumarin rhamnosides, angelicosides I–III (1–3), one undescribed furanocoumarin glucoside, angelicoside IV (4), together with eight known compounds (5–12) were isolated. Their structures were characterized by a combination of UV, IR, NMR, HRESIMS, along with acid hydrolysis and enzymatic hydrolysis. All the isolated compounds were tested for their mushroom tyrosinase inhibitory activities, and compounds 1, 2, and 11 showed moderate activities.